ABILIFY

Product NDC: 59148-007
11-digit product format: 591480007
Labeler code: 59148
Product ID: 59148-007_1b189d15-798d-4bed-a93d-a543ed7abd81
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: ARIPIPRAZOLE
Dosage form: TABLET
Route: ORAL
Labeler: Otsuka America Pharmaceutical, Inc.
Application: NDA021436
Marketing category: NDA
Marketing start: 2002-11-15
Substance: ARIPIPRAZOLE
Active strength: 5 mg/1
Pharmacologic classes: Atypical Antipsychotic [EPC]
NDC exclude flag: No
Listing certified through: 2026-12-31
Current FDA listing: Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N021436-001	ABILIFY	ARIPIPRAZOLE	10MG	TABLET / ORAL	AB	RLD, RS	2002-11-15
N021436-002	ABILIFY	ARIPIPRAZOLE	15MG	TABLET / ORAL	AB	RLD	2002-11-15
N021436-003	ABILIFY	ARIPIPRAZOLE	20MG	TABLET / ORAL	AB	RLD	2002-11-15
N021436-004	ABILIFY	ARIPIPRAZOLE	30MG	TABLET / ORAL	AB	RLD	2002-11-15
N021436-005	ABILIFY	ARIPIPRAZOLE	5MG	TABLET / ORAL	AB	RLD	2002-11-15
N021436-006	ABILIFY	ARIPIPRAZOLE	2MG	TABLET / ORAL	AB	RLD	2002-11-15

Therapeutic equivalence codes#

Application-product, TE code table
Application-product	TE code
N021436-001	AB
N021436-002	AB
N021436-003	AB
N021436-004	AB
N021436-005	AB
N021436-006	AB

Orange Book patents#

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Submission date
N021436-001	9125939	2026-07-28	U-1749	2015-10-07
N021436-001	8759350	2027-03-02	U-1529	2014-07-22
N021436-002	9125939	2026-07-28	U-1749	2015-10-07
N021436-002	8759350	2027-03-02	U-1529	2014-07-22
N021436-003	9125939	2026-07-28	U-1749	2015-10-07
N021436-003	8759350	2027-03-02	U-1529	2014-07-22
N021436-004	9125939	2026-07-28	U-1749	2015-10-07
N021436-004	8759350	2027-03-02	U-1529	2014-07-22
N021436-005	9125939	2026-07-28	U-1749	2015-10-07
N021436-005	8759350	2027-03-02	U-1529	2014-07-22
N021436-006	9125939	2026-07-28	U-1749	2015-10-07
N021436-006	8759350	2027-03-02	U-1529	2014-07-22

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
ABILIFY	ARIPIPRAZOLE	Otsuka America Pharmaceutical, Inc.	c040bd1d-45b7-49f2-93ea-aed7220b30ac	2025-01-29	Boxed warning, Warnings, Adverse reactions	Exact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24 years; there was a reduction in risk with antidepressant use in patients aged 65 years and older [see Warnings and Precautions (5.3) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.3) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 ) Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities) ( 5.1 , 5.2 ) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring ( 5.4 ) Tardive Dyskinesia: Discontinue if clinically appropriate ( 5.5 ) Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain ( 5.6 ) Hyperglycemia/Diabetes Mellitus: Monitor glucose regularly in patients with and at risk for diabetes ( 5.6 ) Dyslipidemia: Undesirable alterations in lipid levels have been observed in patients treated with atypical antipsychotics ( 5.6 ) Weight Gain: Weight gain has been observed with atypical antipsychotic use. Monitor weight ( 5.6 ) Pathological Gambling and Other Compulsive Behaviors: Consider dose reduction or discontinuation ( 5.7 ) Orthostatic Hypotension: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope ( 5.8 ) Leukopenia, Neutropenia, and Agranulocytosis: have been reported with antipsychotics including ABILIFY. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ABILIFY should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors ( 5.10 ) Seizures/Convulsions: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold ( 5.11 ) Potential for Cognitive and Motor Impairment: Use caution when operating machinery ( 5.12 ) Suicide: The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. Closely supervise high-risk patients ( 5.14 ) 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis Increased Mortality Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psycho...

warnings and cautions table

Table 3:Age RangeDrug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients TreatedIncreases Compared to Placebo<1814 additional cases18 to 245 additional casesDecreases Compared to Placebo25 to 641 fewer case≥656 fewer cases

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1) ] Cerebrovascular Adverse Events, Including Stroke [see Warnings and Precautions (5.2) ] Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions (5.3) ] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4) ] Tardive Dyskinesia [see Warnings and Precautions (5.5) ] Metabolic Changes [see Warnings and Precautions (5.6) ] Pathological Gambling and Other Compulsive Behaviors [see Warnings and Precautions (5.7) ] Orthostatic Hypotension [see Warnings and Precautions (5.8) ] Falls [see Warnings and Precautions (5.9) ] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.10) ] Seizures/Convulsions [see Warnings and Precautions (5.11) ] Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.12) ] Body Temperature Regulation [see Warnings and Precautions (5.13) ] Suicide [see Warnings and Precautions (5.14) ] Dysphagia [see Warnings and Precautions (5.15) ] Commonly observed adverse reactions (incidence ≥5% and at least twice that for placebo) were ( 6.1 ): Adult patients with schizophrenia: akathisia Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder Pediatric patients (10 to 17 years) with bipolar mania: somnolence, extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue, vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy Pediatric patients (6 to 18 years) with Tourette's Disorder: sedation, somnolence, nausea, headach...

adverse reactions table

Table 14: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Adult Patients with Bipolar Mania Treated with ABILIFY MonotherapyPreferred TermPercentage of Patients Reporting ReactionABILIFY (n=917)Placebo (n=753) Akathisia134Sedation83Restlessness63Tremor63Extrapyramidal Disorder52

Additional Listing Data#

Finished product: Yes
Brand name base: ABILIFY
Listing expiration: 2026-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
ARIPIPRAZOLE	5 mg/1

Harmonized Identifiers#

Field, Values table
Field	Values
Unii	82VFR53I78
Rxcui	349490, 349545, 349547, 349553, 352307, 352308, 352309, 352310, 402131, 404602, 602964, 615172

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
915afeb5-0b22-42c0-86ea-77abf1c5fe15	Product name	1	20250307
51c1e9bf-32c5-4a7b-b010-f93a90af7b6e	Product name	1	20231010
34645f32-2ac4-41bf-9c61-8107e4764a26	Product name	1	20181210
f8ff9e17-cd6c-4547-98c3-f5db0d1fc25d	Product name	1	20180110
14eaf619-f285-4cd0-9f39-d9dd8f3d9c02	Product name	1	20170824
8223ef47-de85-24dd-a9c7-5a041d2634a2	Product name	9	20170223

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
59148-007-13	2021-08-04	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002
59148-007-35	2021-08-04	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002
59148-007-94	2021-08-04	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002
59148-007-13	2021-07-23	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002
59148-007-35	2021-07-23	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002
59148-007-94	2021-07-23	C162847	48780-1	c7ccaba7-1f9b-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY. ABILIFY ® (aripiprazole) Tablets, for oral use Initial U.S. Approval: 2002

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
59148-007-13	ABILIFY	30 in 1 BOTTLE, PLASTIC	TABLET	30	73
59148-007-35	ABILIFY	100 in 1 BLISTER PACK	TABLET	100	73
59148-007-94	ABILIFY	7 in 1 BLISTER PACK	TABLET	7	73

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
59148-007-13	EA - Each	59148-007	3c930b61-b018-474f-819d-a29725677292	1	2012-07-24
59148-007-35	EA - Each	59148-007	60fe6a8a-fac1-4ce7-98f8-391f3b7232f0	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
HYDROXYPROPYL CELLULOSE	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET [BRYANT RANCH PREPACK]	1000
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
ACESULFAME POTASSIUM	INACTIVE INGREDIENT	23OV73Q5G9	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
ASPARTAME	INACTIVE INGREDIENT	Z0H242BBR1	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
CALCIUM SILICATE	INACTIVE INGREDIENT	S4255P4G5M	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
CROSCARMELLOSE SODIUM	INACTIVE INGREDIENT	M28OL1HH48	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
CROSPOVIDONE	INACTIVE INGREDIENT	68401960MK	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
FRUCTOSE	INACTIVE INGREDIENT	6YSS42VSEV	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
HYDROXYPROPYL CELLULOSE (TYPE H)	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
LACTIC ACID, DL-	INACTIVE INGREDIENT	3B8D35Y7S4	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
METHYLPARABEN	INACTIVE INGREDIENT	A2I8C7HI9T	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
PHENYLALANINE	INACTIVE INGREDIENT	47E5O17Y3R	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
PROPYLENE GLYCOL	INACTIVE INGREDIENT	6DC9Q167V3	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
PROPYLPARABEN	INACTIVE INGREDIENT	Z8IX2SC1OH	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
SODIUM HYDROXIDE	INACTIVE INGREDIENT	55X04QC32I	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
SUCROSE	INACTIVE INGREDIENT	C151H8M554	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
SULFOBUTYLETHER .BETA.-CYCLODEXTRIN	INACTIVE INGREDIENT	2PP9364507	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
TARTARIC ACID	INACTIVE INGREDIENT	W4888I119H	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
WATER	INACTIVE INGREDIENT	059QF0KO0R	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
XYLITOL	INACTIVE INGREDIENT	VCQ006KQ1E	ABILIFY (ARIPIPRAZOLE) TABLET ABILIFY (ARIPIPRAZOLE) SOLUTION ABILIFY DISCMELT (ARIPIPRAZOLE) TABLET, ORALLY DISINTEGRATING ABILIFY (ARIPIPRAZOLE) INJECTION, SOLUTION [OTSUKA AMERICA PHARMACEUTICAL, INC.]	56
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
HYDROXYPROPYL CELLULOSE	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET [H.J. HARKINS COMPANY, INC.]	3
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
ARIPIPRAZOLE	ACTIVE INGREDIENT	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
ARIPIPRAZOLE	ACTIVE MOIETY	82VFR53I78	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
ALUMINUM OXIDE	INACTIVE INGREDIENT	LMI26O6933	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
CELLULOSE, MICROCRYSTALLINE	INACTIVE INGREDIENT	OP1R32D61U	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
FD&C BLUE NO. 2	INACTIVE INGREDIENT	L06K8R7DQK	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
HYDROXYPROPYL CELLULOSE	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
HYDROXYPROPYL CELLULOSE (TYPE H)	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
HYDROXYPROPYL CELLULOSE (TYPE H)	INACTIVE INGREDIENT	RFW2ET671P	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET [CARILION MATERIALS MANAGEMENT]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET [STAT RX USA LLC]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	ABILIFY (ARIPIPRAZOLE) TABLET [TYA PHARMACEUTICALS]	2

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
59148-007	ABILIFY (ARIPIPRAZOLE) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.]	73	Current NDC, Legacy NDC, 3 package rows	20250201_c040bd1d-45b7-49f2-93ea-aed7220b30ac.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
82VFR53I78	ARIPIPRAZOLE	129722-12-9	ARIPIPRAZOLE

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
352307	ABILIFY 10 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352308	ABILIFY 15 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
615172	ABILIFY 2 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352309	ABILIFY 20 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352310	ABILIFY 30 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
404602	ABILIFY 5 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349545	ARIPiprazole 10 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349490	ARIPiprazole 15 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
602964	ARIPiprazole 2 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349553	ARIPiprazole 20 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349547	ARIPiprazole 30 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
402131	ARIPiprazole 5 MG Oral Tablet	PSN	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352307	aripiprazole 10 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352308	aripiprazole 15 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
615172	aripiprazole 2 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352309	aripiprazole 20 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352310	aripiprazole 30 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
404602	aripiprazole 5 MG Oral Tablet [Abilify]	SBD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349545	aripiprazole 10 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349490	aripiprazole 15 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
602964	aripiprazole 2 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349553	aripiprazole 20 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
349547	aripiprazole 30 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
402131	aripiprazole 5 MG Oral Tablet	SCD	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352307	Abilify 10 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352308	Abilify 15 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
615172	Abilify 2 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352309	Abilify 20 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
352310	Abilify 30 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
404602	Abilify 5 MG Oral Tablet	SY	c040bd1d-45b7-49f2-93ea-aed7220b30ac	73
404602	ABILIFY 5 MG Oral Tablet	PSN	bbc2b53b-b712-49eb-b2ce-766bcc448616	3
404602	ABILIFY 5 MG Oral Tablet	PSN	d8275c2d-f42d-4f32-aa9f-03a202c8e99f	3
402131	ARIPiprazole 5 MG Oral Tablet	PSN	d8275c2d-f42d-4f32-aa9f-03a202c8e99f	3
402131	ARIPiprazole 5 MG Oral Tablet	PSN	bbc2b53b-b712-49eb-b2ce-766bcc448616	3
404602	aripiprazole 5 MG Oral Tablet [Abilify]	SBD	bbc2b53b-b712-49eb-b2ce-766bcc448616	3
404602	aripiprazole 5 MG Oral Tablet [Abilify]	SBD	d8275c2d-f42d-4f32-aa9f-03a202c8e99f	3
402131	aripiprazole 5 MG Oral Tablet	SCD	d8275c2d-f42d-4f32-aa9f-03a202c8e99f	3
402131	aripiprazole 5 MG Oral Tablet	SCD	bbc2b53b-b712-49eb-b2ce-766bcc448616	3
404602	Abilify 5 MG Oral Tablet	SY	bbc2b53b-b712-49eb-b2ce-766bcc448616	3
404602	Abilify 5 MG Oral Tablet	SY	d8275c2d-f42d-4f32-aa9f-03a202c8e99f	3
615172	ABILIFY 2 MG Oral Tablet	PSN	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
404602	ABILIFY 5 MG Oral Tablet	PSN	634b6431-48ca-480c-a4d8-0ba022bbf0f4	2
404602	ABILIFY 5 MG Oral Tablet	PSN	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
602964	ARIPiprazole 2 MG Oral Tablet	PSN	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
402131	ARIPiprazole 5 MG Oral Tablet	PSN	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
402131	ARIPiprazole 5 MG Oral Tablet	PSN	634b6431-48ca-480c-a4d8-0ba022bbf0f4	2
615172	aripiprazole 2 MG Oral Tablet [Abilify]	SBD	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
404602	aripiprazole 5 MG Oral Tablet [Abilify]	SBD	634b6431-48ca-480c-a4d8-0ba022bbf0f4	2
404602	aripiprazole 5 MG Oral Tablet [Abilify]	SBD	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
602964	aripiprazole 2 MG Oral Tablet	SCD	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
402131	aripiprazole 5 MG Oral Tablet	SCD	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
402131	aripiprazole 5 MG Oral Tablet	SCD	634b6431-48ca-480c-a4d8-0ba022bbf0f4	2
615172	Abilify 2 MG Oral Tablet	SY	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2
404602	Abilify 5 MG Oral Tablet	SY	634b6431-48ca-480c-a4d8-0ba022bbf0f4	2
404602	Abilify 5 MG Oral Tablet	SY	16710a27-aa76-4dd7-92e8-7d3c7efe3e42	2

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
59148-007-13	59148000713	30 TABLET in 1 BOTTLE, PLASTIC (59148-007-13)	30 tablet	2002-11-15	0000-00-00	No	No	Current
59148-007-35	59148000735	100 TABLET in 1 BLISTER PACK (59148-007-35)	100 tablet	2002-11-15	0000-00-00	No	No	Current
59148-007-94	59148000794	7 TABLET in 1 BLISTER PACK (59148-007-94)	7 tablet	2002-11-15	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
ABILIFY	Otsuka America Pharmaceutical, Inc.	2025-01-29	HUMAN PRESCRIPTION DRUG LABEL	73
ABILIFY	Bryant Ranch Prepack	2019-09-12	HUMAN PRESCRIPTION DRUG LABEL	1002
ABILIFY	Carilion Materials Management	2016-08-06	HUMAN PRESCRIPTION DRUG LABEL	3
ABILIFY	TYA Pharmaceuticals	2014-07-03	HUMAN PRESCRIPTION DRUG LABEL	2
ABILIFY	H.J. Harkins Company, Inc.	2012-01-16	HUMAN PRESCRIPTION DRUG LABEL	3
ABILIFY	STAT RX USA LLC	2011-02-07	HUMAN PRESCRIPTION DRUG LABEL	2

ABILIFY

Orange Book products#

Therapeutic equivalence codes#

Orange Book patents#

openFDA label cross-check#

Boxed warning cross-check#

boxed warning

Warnings cross-check#

warnings and cautions

warnings and cautions table

Adverse reactions cross-check#

adverse reactions

adverse reactions table

Additional Listing Data#

Related Records#

Active Ingredients#

Harmonized Identifiers#

DailyMed Product Concepts#

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

DailyMed Billing Units#

DailyMed Socrata Ingredients#

DailyMed Dashboard NDC Coverage#

Related Records#

Related UNII Ingredients#

DailyMed RxNorm Mappings#

Packages#

Related DailyMed Labels#